Company profile
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic
- CEO
- Ms. Carrie L. Bourdow
- Headquarters
- Chesterbrook, PA, United States
- Employees
- 23
- IPO date
- Jan 31, 2014
- Sector
- Healthcare
- Industry
- Biotechnology